Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD

Respiratory Medicine

Volumn 107, Issue 4, 2013, Pages 542-549

  Hagedorn, Cordula ^a   Kässner, Frank ^b   Banik, Norbert ^c   Ntampakas, Paris ^c   Fielder, Karin ^d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Center for Pneumology and Sleep Medicine   (Germany)

^c GLAXOSMITHKLINE   (Germany)

^d Winicker Norimed   (Germany)

Author keywords

COPD; Exacerbations rate; Health care utilization

Indexed keywords

FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; SALMETEROL XINAFOATE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COST OF ILLNESS; CYANOSIS; DISEASE EXACERBATION; DRUG EFFECT; DRUG WITHDRAWAL; DYSPHONIA; DYSPNEA; EVENING DOSAGE; FEMALE; GERMANY; HEALTH CARE UTILIZATION; HEART ARRHYTHMIA; HUMAN; INHALER; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; THRUSH;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AGED; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; DELIVERY OF HEALTH CARE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HEALTH CARE COSTS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84875258524     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2012.12.020     Document Type: Article

References (17)

1. American Thoracic Society/European Respiratory Society Task Force Standards for the diagnosis and management of patients with COPD [Internet]. Version 1.2 2004 American Thoracic Society New York [updated 2005 September 8]. Available from: http://www.thoracic.org/go/copd
2. From the global strategy for the diagnosis, management and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD) 2008 Available from: http://www.goldcopd.org
3. B.R. Celli, N.E. Thomas, J.A. Anderson, G.T. Ferguson, C.R. Jenkins, and P.W. Jones Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study Am J Respir Crit Care Med 178 2008 332 338
4. D.A. Mahler, J.F. Donohue, R.A. Barbee, M.D. Goldman, N.J. Gross, and M.E. Wisniewski Efficacy of salmeterol xinafoate in the treatment of COPD Chest 115 1999 957 965
5. P.S. Burge, P.M. Calverley, P.W. Jones, S. Spencer, J.A. Anderson, and T.K. Maslen Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial BMJ 320 2000 1297 1303
6. P.W. Jones, L.R. Willits, P.S. Burge, and P.M. Calverley Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations Eur Respir J 21 2003 68 73
7. P.M. Calverley, R. Pauwels, J. Vestbo, P. Jones, N. Pride, and A. Gulsvik Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial Lancet 361 2003 449 456
8. P.M. Calverley, J.A. Anderson, B. Celli, G.T. Ferguson, C. Jenkins, and P.W. Jones Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med 356 2007 775 789
9. P. Kardos, M. Wencker, T. Glaab, and C. Vogelmeier Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease Am J Respir Crit Care Med 175 2007 144 149
10. J. Garcia-Aymerich, I. Serra Pons, D.M. Mannino, A.K. Maas, D.P. Miller, and K.J. Davis Lung function impairment, COPD hospitalisations and subsequent mortality Thorax 66 7 2011 585 590
11. J.R. Hurst, J. Vestbo, A. Anzueto, N. Locantore, H. Müllerova, and R. Tal-Singer Susceptibility to exacerbation in chronic obstructive pulmonary disease N Engl J Med 363 12 2010 1128 1138
12. R. Rodriguez-Roisin Toward a consensus definition for COPD exacerbations Chest 117 2000 398 401
13. T. Agh, A. Inotai, and A. Meszaros Factors associated with medication adherence in patients with chronic obstructive pulmonary disease Respiration 2011 10.1159/000324453
14. M. Takemura, K. Mitsui, R. Itotani, M. Ishitoko, S. Suzuki, and M. Matsumoto Relationships between repeated instruction on inhalation therapy, medication adherence, and health status in chronic obstructive pulmonary disease Int J Chron Obstruct Pulmon Dis 6 2011 97 104
15. C.R. Jenkins, P.W. Jones, P.M. Calverley, B. Celli, J.A. Anderson, and G.T. Ferguson Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study Respir Res 10 2009 59
16. J.P. Zheng, L. Yang, Y.M. Wu, P. Chen, Z.G. Wen, and W.J. Huang The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD Chest 132 2007 1756 1763
17. J.A. Wedzicha, P.M. Calverley, T.A. Seemungal, G. Hagan, Z. Ansari, and R.A. Stockley The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide Am J Respir Crit Care Med 177 2008 19 26